Abstract
In this issue of Blood, Schmitt et al address the biology and safety of T cells engineered to express T-cell receptor (TCR) variants endowed with enhanced affinity for tumor-associated antigens.
MeSH terms
-
Animals
-
Antigens, Neoplasm / immunology*
-
Autoantigens / immunology*
-
Genetic Therapy*
-
Humans
-
Receptors, Antigen, T-Cell / immunology*
-
Thymus Gland / immunology*
Substances
-
Antigens, Neoplasm
-
Autoantigens
-
Receptors, Antigen, T-Cell